Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Rating of “Buy” by Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company.

A number of brokerages have weighed in on BAYRY. JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 20th. Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Finally, Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd.

Bayer Aktiengesellschaft Stock Up 0.6%

Shares of Bayer Aktiengesellschaft stock opened at $13.58 on Monday. The company has a market capitalization of $53.37 billion, a P/E ratio of -150.87, a price-to-earnings-growth ratio of 4.88 and a beta of 0.67. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71. The business has a 50-day moving average of $11.88 and a two-hundred day moving average of $9.44. Bayer Aktiengesellschaft has a 1 year low of $5.30 and a 1 year high of $13.98.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.